QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

IRD

QT62Opus Genetics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
4.07
+0.01+0.25%
OverviewShort InterestFilings
IRDQT62Opus Genetics, Inc.·NASDAQ
OverviewShort InterestFilings
4.07+0.25%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.31
Insider Own-
Shs Outstand-
Perf Week4.09%
Market Cap335.22MForward P/E-EPS next Y-0.73Insider Trans-Shs Float-Perf Month-4.46%
Enterprise Value301.19MPEG0.87EPS next Q-0.15Inst Own-Short Float-Perf Quarter-11.14%
Income-10157084.00P/S27.97EPS this Y17.13%Inst Trans-Short Ratio-Perf Half Y90.19%
Sales11.98MP/B-EPS next Y33.16%ROA-160.11%Short Interest-Perf YTD102.49%
Book/sh-P/C-EPS next 5Y-ROE6068.79%52W High5.81 -29.95%Perf Year340.67%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-74.91%52W Low0.90 351.67%Perf 3Y-
Dividend Est.-EV/EBITDA-2.88Sales past 3/5Y-29.53% -Gross Margin49.64%Volatility4.46% 4.54%Perf 5Y-
Dividend TTM-EV/Sales25.14EPS Y/Y TTM65.12%Oper. Margin-359.13%ATR (14)0.30Perf 10Y-
Dividend Ex-Date-Quick Ratio7.13Sales Y/Y TTM9.09%Profit Margin-892.36%RSI (14)44.67Recom2.00
Dividend Gr. 3/5Y-Current Ratio7.13EPS Q/Q34.48%SMA20-1.00%Beta1.26Target Price8.50
Payout0.00%Debt/Eq-0.57Sales Q/Q-50.00%SMA50-14.32%Rel Volume1.21Prev Close4.06
Employees18LT Debt/Eq-0.57EarningsAug 12SMA20028.74%Avg Volume876.23KPrice4.07
IPO DateJan 19, 2015Option/ShortYes / YesEPS/Sales Surpr.-18.75% 33.33%Net Debt/EBITDA0.32Volume1,056,502Change0.25%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-17-26ReiteratedH.C. Wainwright$8.00
May-21-26InitiatedLeerinkOutperform$10
Mar-11-26ReiteratedCraig-Hallum$9.00
Jan-20-26InitiatedBTIGBuy$7.00
Nov-25-25InitiatedPiper SandlerOverweight$7.00
Latest News
Jun-17-26
Jun-17-2608:04AM
HC Wainwright & Co. Reiterates Buy on Opus Genetics, Maintains $8 Price TargetBenzinga
05:52AM
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases TranscriptSeekingAlpha
Jun-16-26
Jun-16-2604:33PM
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases - SlideshowSeekingAlpha
Jun-15-26
Jun-15-2609:57AM
Citizens Reiterates Market Outperform on Opus Genetics, Maintains $11 Price TargetBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue121411
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
600
Gross Profit61411
Selling, General and Administrative Excl. Other222218
Research and Development333127
Other Operating Expense-6028
Operating Income-42-39-62
Interest Expense210
Unusual Expense
———
Non-Operating Income (Expense)6210-5
Net Income Before Taxes-107-50-58
Income Taxes
000
Consolidated Net Income-107-50-58
Net Income From Continuing Operations-107-50-58
Net Income-107-50-58
EPS (Recurring)-1.31-0.80-2.15
EPS (Basic, Before Extraordinaries)-1.31-0.80-2.15
EPS (Diluted)-1.31-0.80-2.15
EBITDA-104-48-58
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio294.7489.30—
Gross Margin50.00100.00100.00
Operating Margin-350.00-278.57-563.64
Net Margin-891.67-357.14-527.27
Shares Outstanding86962227
Market Capitalization3,5371,250—
Operating Lease Expense
———
Insider Trading Volume
$4.50$3.98$3.45$2.92$2.40● Close Price0.00M2.15M4.30M6.45M8.60MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Foundation Fighting Blindness Retinal Degeneration Funddirector, other: See RemarksMay 18 '26Sale4.351,700,0007,395,0003,792,171May 20 12:00 AM
YERXA BENJAMIN RPresidentApr 23 '26Sale5.247,47039,121711,535Apr 27 12:00 AM
SCHACHLE JOSEPH KChief Operating OfficerApr 23 '26Sale5.224,69724,519296,084Apr 27 12:00 AM
Magrath GeorgeChief Executive OfficerApr 23 '26Sale5.229,51149,6471,741,344Apr 27 12:00 AM
Gagnon Robert E.Chief Financial OfficerApr 23 '26Sale5.187,84240,658592,158Apr 27 12:00 AM
Zaremba Rabourn AmyHead of Fin. Quality AssuranceApr 23 '26Sale5.201,6418,540188,671Apr 27 12:00 AM
Jayagopal AshwathChief Scientific & Dev. Ofc.Apr 23 '26Sale5.197,54239,156509,233Apr 27 12:00 AM
SCHACHLE JOSEPH KChief Operating OfficerMar 16 '26Sale5.253,71919,525300,781Mar 18 12:00 AM
Zaremba Rabourn AmyHead of Fin. Quality AssuranceMar 16 '26Sale5.252,81614,770190,312Mar 18 12:00 AM
Magrath GeorgeChief Executive OfficerMar 16 '26Sale5.2124,438127,3271,750,855Mar 18 12:00 AM
Jayagopal AshwathChief Scientific & Dev. Ofc.Mar 16 '26Sale5.123,71919,046516,775Mar 18 12:00 AM
Gallagher CamDirectorDec 29 '25Buy1.97164,000323,6941,891,430Dec 31 12:00 AM
Foundation Fighting Blindness Retinal Degeneration Funddirector, other: See RemarksDec 09 '25Sale2.154,000,0008,600,0005,492,171Dec 11 12:00 AM
Magrath GeorgeChief Executive OfficerDec 26 '24Buy0.98100,00097,600599,150Dec 30 12:00 AM
YERXA BENJAMIN RPresidentNov 21 '24Buy0.9810,0009,834342,800Nov 25 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR